Drug Trial Radar · NCT06984822
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Vastra Gotaland RegionGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).
Conditions
- Diabetic Macular Edema
- Visual Impairment
- Diabetes Mellitus
- Hyperglycaemia (Diabetic)
- Oxidative Stress
- Vascular Endothelial Growth Factor
- VEGF
Interventions
Anti-VEGF treatmentDrug
Treatment with intravitreal anti-VEGF treatment
Dexamethasone implantDevice
Treatment with Dexamethasone implant
Treatment with intravitreal anti-VEGF OR Dexamethasone implantOther
Treatment with intravitreal anti-VEGF OR treatment with Dexamethasone implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum levels of Vascular Endothelial Growth Factor (VEGF)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of interleukin 6 (IL-6)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of interleukin 8 (IL-8)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of monocyte chemoattractant protein 1 (MCP-1)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of angiopoietin 2 (Ang-2)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of placental growth factor (PlGF)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of tumor necrosis factor alpha (TNF-a)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
- Serum levels of intercellular adhesion molecule 1 (ICAM-1)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sahlgrenska University Hospital, Department of Ophthalmology
Mölndal, Sweden · Recruiting
Ögonmottagning Mölndal/SU
Mölndal, Sweden · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.